Leqselvi (deuruxolitinib) / Sun Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«123»
  • ||||||||||  Leqselvi (deuruxolitinib) / Sun Pharma
    Enrollment open, Phase classification, Trial completion date, Trial primary completion date:  Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) -  May 17, 2021   
    P2/3,  N=142, Recruiting, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | Phase classification: P2 --> P2/3 | Trial completion date: May 2022 --> May 2023 | Trial primary completion date: Feb 2022 --> Feb 2023
  • ||||||||||  Leqselvi (deuruxolitinib) / Sun Pharma
    Trial completion:  Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects (clinicaltrials.gov) -  Apr 7, 2021   
    P1,  N=22, Completed, 
    Active, not recruiting --> Recruiting | Phase classification: P2 --> P2/3 | Trial completion date: May 2022 --> May 2023 | Trial primary completion date: Feb 2022 --> Feb 2023 Recruiting --> Completed
  • ||||||||||  Leqselvi (deuruxolitinib) / Sun Pharma
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) -  Apr 6, 2020   
    P2,  N=142, Active, not recruiting, 
    Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=100 --> 142 | Trial completion date: Mar 2021 --> May 2022 | Trial primary completion date: Dec 2020 --> Feb 2022
  • ||||||||||  Jakafi oral (ruxolitinib) / Novartis, Incyte, Xeljanz (tofacitinib) / Pfizer
    Journal:  JAK inhibition in the treatment of alopecia areata - a promising new dawn? (Pubmed Central) -  Jan 24, 2020   
    Positive results in early phase 1 and phase 2 clinical trials have enabled the commencement of phase 3 clinical trials and there is now a growing sense of optimism among patients with long-standing, treatment-refractory AA. Further work is required to determine the optimal dose and treatment duration and whether maintenance therapy is universally required.